Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
910 results
  • [A Case of Pericardial Effusion Induced by Nivolumab for Metastatic Renal Cell Carcinoma]. [Journal Article]
    Hinyokika Kiyo 2019; 65(8):329-332Fukae S, Tanaka R, … Yamaguchi S
  • A 72-year-old female with left renal cell carcinoma and lymphadenopathy had undergone hand-assisted laparoscopic left nephrectomy and dissection of the lymph node (papillary renal cell carcinoma, type 2, pT3a pN2 M1). She had been treated with adjuvant chemotherapy with sunitinib, temsirolimus and pazopanib. However, the patient was started on nivolumab due to disease progression. After receiving…
  • Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A. [Journal Article]
    Oncotarget 2019; 10(50):5168-5180Bourn J, Pandey S, … Cekanova M
  • Among challenges of targeted therapies is the activation of alternative pro-survival signaling pathways in cancer cells, resulting in an acquired drug resistance. Cyclooxygenase-2 (COX-2) is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer. Fluorocoxib A is an optical imaging agent that selectively targets COX-2. In this stu…
  • [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. [Journal Article]
    Aktuelle Urol 2019Miller K, Bergmann L, … Kuczyk MA
  • Due to novel therapies, the prognosis of patients with metastatic renal cell carcinoma has improved significantly. A median overall survival of more than two years is a realistic goal. Immunotherapies with checkpoint inhibitors are new first-line and second-line options. Sunitinib, Pazopanib, Tivozanib and the combination of Bevacizumab + interferon alpha are approved for first-line therapy, rega…
  • Emerging therapeutic agents for genitourinary cancers. [Review]
    J Hematol Oncol 2019; 12(1):89Zarrabi K, Paroya A, Wu S
  • The treatment of genitourinary malignancies has dramatically evolved over recent years. Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are the most commonly encountered genitourinary malignancies and represent a heterogeneous population of cancers, in both histology and approach to treatment. However, all three cancers have undergone paradigm shifts in thei…
New Search Next